Alivus Life Sciences Ltd

- No plans for new debt in FY’26-27 as stated by Yasir Rawjee: "No, we are not planning any debt." - The company continues to invest heavily in CAPEX (around Rs.550-600 crore for FY’26) funded through internal accruals and existing cash reserves. - The company remains net debt-free with strong cash flow from operations and cash equivalents of Rs.549 crores as of March 31, 2025. - There is no mention of any planned equity fundraising in the provided text. - Overall, the company appears focused on growth funded through existing resources without external debt or equity raising in the near term.

- Total planned CAPEX for FY’26 is upwards of Rs. 550 crores (Rs. 550-600 crores range). - Major CAPEX includes: - Greenfield expansion in Solapur. - Brownfield expansions in Ankleshwar and Dahej to be completed this year. - New R&D center near Mumbai with Rs. 70-80 crores allocated. - The 2650 KL volume expansion initially planned for FY’27 is now pushed to FY’28 due to brownfield expansions providing sufficient capacity for next 2-3 years. - Asset turnover may be lower initially during this investment phase but expected to reach around 2x gradually. - Focus remains on completing brownfield expansions and Solapur Phase 1 (300 KL) by Q4 FY’26. - No new debt planned for FY’26-27; company remains net debt-free. - Strategic collaborations and platform developments are ongoing with updates expected in second half or end of FY’26.

- FY’26 volume growth expected in mid-teens, driven by new product launches and opening of new markets. - Revenue growth projected to be in high single digits due to pricing erosion despite volume growth. - Incremental volume growth primarily from newer product sites, though base products continue solid volume growth. - CDMO business expected to grow significantly with 4th project reaching full potential by end FY’25 and 5th project obtaining regulatory approval in second half FY’26. - Longer-term, growth is backed by a strong pipeline with product launches aligned with patent expiries starting FY’28. - Company remains optimistic about future trajectory supported by favorable demand environment and healthy order book. - Margins expected to stabilize in the 28% to 30% range going forward.

- **Volume Growth:** Mid-teens volume growth expected in FY’26 driven by new product launches and market expansion. - **Revenue Growth:** High single-digit revenue growth anticipated due to pricing pressures despite volume growth. - **CDMO Business:** Targeting 4x growth from FY’24 levels by FY’28 with Rs.500-600 crore revenue, fifth project approval expected H2 FY’26. - **Margins:** Operating margins expected to stabilize in the 28%-30% range going forward. - **Earnings:** PAT margin for FY’25 stood at 20.3%, with Q4 FY’25 PAT margin at 21.8%, indicating steady profit growth. - **Capex Impact:** Short-term impact on asset turns due to ongoing capex, but expected to normalize with growth projects coming online (Dahej, Ankleshwar expansions by Nov-Dec, Solapur by Q4). - **Long-Term Outlook:** Optimistic growth trajectory supported by strong order book, pipeline, and favorable demand environment.

- The CDMO business has a small base with three commercial projects currently driving volume. - The 4th CDMO project started commercializing in Q3 of the previous year but is on a slow uptake, expected to reach full potential by end of the current year. - The 5th CDMO project is under regulatory approvals, with an anticipated approval for use as an API source in the second half of FY’26. - There are ongoing discussions and multiple projects ("irons in the fire") in the CDMO pipeline aimed at bringing more projects by late FY’26 or early FY’27. - Average size of CDMO contracts is around Rs.50 to Rs.60 crore, targeting lifecycle management and 505 B2 therapies. - The company expects a back-loaded CDMO order book performance for the current year, with growth kicking in more towards the latter half.